Genmab — Marts 2019

[Sukkeralf]

E L I guess that comment is because NICE mainly base their reimbursement on OS data

[E_L]

yes, i guess you are correct, that is what they base their cost effectiveness study on, but it feels weird to say that it is difficult to measure because they live too long... Anyway, another small step..
.

[Bulder]

What does this mean? They recommend the treatment, but will not reimburse it?

[E_L]

NHS will not directly fund it, it will be reimbursed out of the Cancer Drugs Fund (CDF), just like currently is the case with mono

[peter12]

Genmab var shortet 4,04% 28 feb. Det har ligget på 3-4% det sidste år. Det er positioner over 0,2%

[Joakim_Von_And]

Ja,, kunne der komme et bud , så de hurtigt ville i 0 ,, det ville glæde mig at de brændte nallerne lidt...

[StockBull]

2.5 - 5% det sıdste aars tıd

[StockBull]

1.5 aars tıd

[Sukkeralf]

Så kender man Genmab igen - svag som i svag.

[Tandfeen-2]

Desværre også på en grøn dag

[Helge_LarsenPI-redaktør]

Genmab og Novo følges ad med minus 0,22 og 0,26% i dag. Værre er det ikke.

[concillado]

GEN's kurs klargør blot at lægge sig favorabelt til os trofaste investorer, så vi kan full value, når vi skal brænde vores overskydende skat af lige om lidt!

[E_L]

New trial : Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) https://clinicaltrials.gov/ct2/show/NCT03871829

[E_L]

and it looks like they will give this one another try https://clinicaltrials.gov/ct2/history/NCT03346135?A=5&B=6&C=merged

[E_L]

and the Tisotumab Vedotin safety study published the results
https://clinicaltrials.gov/ct2/history/NCT02552121?A=10&B=11&C=merged

[E_L]

well , at least NICE itself also calls daratumumab a “potentially game-changing” treatment https://twitter.com/NICEcomms/status/1105468491388338176

[Bulder]

Note the inverted commas

[E_L]

[peter12]

They don't believe it has proved to be cost effective yet but : "The patient experts stated that the psychological benefit of delaying a second relapse had not been captured in the quality-of-life measure in the trial. The committee agreed that this had not been captured in the model."

[E_L]

Janssen Submits Application to U.S. FDA … Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
https://www.prnewswire.com/news-releases/janssen-submits-application-to-us-fda-seeking-approval-of-darzalex-daratumumab-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible-300811239.html